Navigation Links
Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
Date:10/3/2008

New Rochelle, NY, October 3, 2008Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). The payoff for successful molecular diagnostic products can be significant as Kalorama Information predicts that this market currently exceeds $3.2 billion worldwide and will reach $5.4 billion in four years, according to an article in the October 1 issue of GEN.

"Molecular diagnostic products are based on cutting-edge research in two of the most promising biotechnologies, genomics and proteomics. These novel tests also utilize sophisticated analytical techniques such as microarrays and mass spectrometry," notes John Sterling, Editor-in-Chief of GEN. "Molecular diagnostics are particularly applicable to the early detection of cancer."

Affymetrix and Illumina have both created array-based products that enable high-speed analysis of DNA, RNA, and proteins as tools for disease research, drug development, and molecular tests. These gene-sequencing tools are being applied at an earlier stage.

Genetic tests can optimize drug therapy, and companion diagnostics are being touted as a method to better define a patient's need or predict clinical outcome from a specific drug. The FDA recently approved a HER-2 test from Invitrogen called Spot-Light that can be used to identify breast cancer patients who are candidates for treatment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of Erbitux for metastatic colorectal cancer.

Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostics and biopharmaceuticals and is well positioned for the future with products in oncology and infectious disease. Its genetic tests include CYP450 for drug metabolism studies and HER-2 for
'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology technology :

1. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
2. Genetically Modified Canola Plantings Reach 90 Percent in Canada
3. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
4. A Better Tomorrow Treatment Center Inc., Forterus Inc.s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior
5. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
6. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
7. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
8. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
9. deCODE genetics Announces Second Quarter 2008 Financial Results
10. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
11. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...c. 1 GeoVax Labs, Inc. ...lanta-based, biopharmaceutical company developing ... Immunodeficiency Virus) and other infectious agen.... ,, "Today is the 21st World AIDS Day and as w... with the HIV/AIDS pandemic, we remain focused and...
(Date:12/1/2009)... California waste-to-energy firm claims first plac...ation, smallest footprint, salable pure gas, bypro... (PRWEB) December 15, 2009 -- The fi...ve organic waste-to-energy process will take place...ry. , , ,This biowaste process known as VRAD©...
(Date:11/30/2009)...Minn., Nov. 30 Acuo Technologies, ...ement software, data migration tools and services,... and Clinics for a new Vendor Neutral Archive (VNA...s the Allina network of hospitals, clinics and aff...the Acuo Technologies DICOM Services Grid(TM) Soft...
(Date:11/30/2009)...30 Dr. Jessica Torrente, Assistant...rsity Medical Center in Washington, D.C., demonstr...mma Imaging (BSGI) in clinical practice as an adju...ancer today at the annual meeting of the Radiologi...rpose of the exhibit was to demonstrate how BSGI i...
Breaking Biology Technology:GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 2GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 3GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 4GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 5GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 6First Public Showing of Innovative Waste-to-Energy Process 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2
...TC-NCI-AACR Symposium --, SEATTLE and GENEVA, Oct...q: DNDN ) today presented preclinical data on its...ets Trp-p8 (a,transmembrane cation channel protein...rapeutic cancer target., The poster, titled, "Pre...Cancer/ Benign Prostate Hyperplasia Target," was p...
...United,Therapeutics Corporation (Nasdaq: UTHR ) a... quarter financial results before market open on,T...ill host a half-hour teleconference on Thursday,Oc...econference is,accessible by dialing 1-800-603-177...29. A rebroadcast of the teleconference will be av...
...rGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical comp...novel cancer therapies, today presented data on MP...nal posters, at the 20th,EORTC-NCI-AACR Symposium ...Geneva, Switzerland. MP-470, an orally bio-availab...d encouraging tumor regression results in,the firs...
Other Biology Technology:Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist 2Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist 3SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy 2SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy 3SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy 4
(Date:12/1/2009)...ty cancer researchers have developed a tumor-atta...blocks the growth of new tumor blood vessels. , ... cancer cells oncolytic viruses might be more ef...so carry a gene for a protein that inhibits blood-...n, is normally produced in the brain. In this stud...
(Date:12/1/2009)...cks by sharks can be solved with a new technique t...ey put on their victims, according to a University...method analogous to analyzing human fingerprints, ...omparing shark bites to the jaws and teeth of the ...of the International Shark Attack File, which is h...
(Date:12/1/2009)...able mystery, and it is a question which has conti...owering plants evolve and how did they come to dom...gy Letters reveals the evolutionary trigger which...petitive advantage over rival species, leading to ..., by Dr Tim Brodribb and Dr Taylor Field of the U...
Breaking Biology News(10 mins):Tumor-attacking virus strikes with 'one-two punch' 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3How did flowering plants evolve to dominate Earth? 2Palatin Technologies Inc to Raise 243 1 Million in Registered Direct Offering 13531 1Palatin Technologies Inc to Raise 243 1 Million in Registered Direct Offering 13531 2Palatin Technologies Inc to Raise 243 1 Million in Registered Direct Offering 13531 3New insights into limb formation 9549 1New insights into limb formation 9549 2Ohio KePRO Awarded Medicare Beneficiary Protection Program Support Contract 54354 1Ohio KePRO Awarded Medicare Beneficiary Protection Program Support Contract 54354 2Ohio KePRO Awarded Medicare Beneficiary Protection Program Support Contract 54354 3
...n University, Glassboro, N.J.; the University of P...ity may lead to better diagnosis of early-stage Al...stitutes of Health’s National Institute on Aging s...hree years, they determined early Alzheimer’s coul...ting electroencephalogram (EEG) signals. The study...
...opsin, the light-sensitive protein found in many m...t of Energy,s Lawrence Berkeley National Laborator...at Berkeley have demonstrated that when the abilit...d with proteorhodopsin will switch to solar power ...arch shows that proteorhodopsin contributes to a b...
...eart problems when mothers carry particular antibo... to an abstract presented by Yale School of Medici...edicine Conference February 9 in San Francisco. ,...ore birth and impairs the heart,s electrical signa...ries a 20 percent death rate and nearly all surviv...
Other Biology News:Study shows hope for early diagnosis of Alzheimer's 2Study shows hope for early diagnosis of Alzheimer's 3Study shows hope for early diagnosis of Alzheimer's 4Shedding new light on proteorhodopsin 2Shedding new light on proteorhodopsin 3
Rabbit Anti-Human NIRF Polyclonal Antibody, Unconjugated from Abcam
Alu I from New England Biolabs
Rabbit Anti-ZNF261 Polyclonal Antibody, Unconjugated from Abcam
SexA I from New England Biolabs
Biology Products: